Dear ALS community,

We are pleased to share that Prilenia has entered into a collaboration and license agreement with Ferrer for the commercialization and co-development of pridopidine in Europe and other select markets. Prilenia will retain full rights to pridopidine in other major geographies, including North America, Japan and all other countries in Asia as well as Australia.

So, what does this mean?

This agreement marks an important step forward for Prilenia in our mission to develop and provide sustainable access to transformative medicines for people affected by devastating neurodegenerative diseases.

We are proud to partner with Ferrer as they continue to grow their presence throughout Europe and key international markets with particular focus on innovative products for rare diseases. As the highest rated pharma B corp in the world, Ferrer will ensure a strong patient and social justice approach – a cornerstone of Prilenia’s values as well. A B corp is a business that acts in ways that benefit society as a whole. What defines them is the belief that the purpose of a company is not just profits but social good.

By combining our unique strengths and shared commitment to patient communities, we believe that this partnership has the potential to accelerate the delivery of pridopidine to the thousands of people who are waiting for a new treatment option, as well as broaden its impact through additional indications in the future.

The next steps for pridopidine in ALS remain unchanged.

Prilenia and Ferrer plan to initiate a single, pivotal Phase 3 trial to evaluate the efficacy and safety of pridopidine, seeking to confirm findings from the Phase 2 HEALEY ALS Platform Trial. We will provide an update to the ALS community on expected timelines when they are determined.

To learn more about this news and pridopidine, please read our press release here.

We remain dedicated to individuals, families, caregivers and communities affected by ALS, and thank you all for your ongoing support and collaboration as we continue to advance pridopidine as a potential treatment option for people living with ALS and other neurodegenerative diseases.

Sincerely,

Dr. Michael R. Hayden, CEO
On behalf of the team at Prilenua